Histogen (HSTO) Competitors $0.0005 0.00 (0.00%) As of 09/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock HSTO vs. PXMD, CALA, CLVR, EFTR, ONCSQ, ATNFW, LBPSW, AEHAW, AIMDW, and ALVOWShould you be buying Histogen stock or one of its competitors? The main competitors of Histogen include PaxMedica (PXMD), Calithera Biosciences (CALA), Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), OncoSec Medical (ONCSQ), 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), and Alvotech (ALVOW). These companies are all part of the "pharmaceutical products" industry. Histogen vs. Its Competitors PaxMedica Calithera Biosciences Clever Leaves eFFECTOR Therapeutics OncoSec Medical 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech PaxMedica (NASDAQ:PXMD) and Histogen (NASDAQ:HSTO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Which has more volatility & risk, PXMD or HSTO? PaxMedica has a beta of -0.99, indicating that its share price is 199% less volatile than the S&P 500. Comparatively, Histogen has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Do insiders & institutionals have more ownership in PXMD or HSTO? 4.9% of PaxMedica shares are held by institutional investors. 1.0% of PaxMedica shares are held by insiders. Comparatively, 3.3% of Histogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is PXMD or HSTO more profitable? Histogen's return on equity of 0.00% beat PaxMedica's return on equity.Company Net Margins Return on Equity Return on Assets PaxMedicaN/A -3,167.89% -560.35% Histogen N/A N/A N/A Which has preferable valuation & earnings, PXMD or HSTO? Histogen has higher revenue and earnings than PaxMedica. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPaxMedicaN/AN/A-$18.29MN/AN/AHistogen$19K0.11-$10.62M-$2.810.00 Does the media refer more to PXMD or HSTO? In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Histogen'saverage media sentiment score. Company Overall Sentiment PaxMedica Neutral Histogen Neutral SummaryHistogen beats PaxMedica on 6 of the 7 factors compared between the two stocks. Get Histogen News Delivered to You Automatically Sign up to receive the latest news and ratings for HSTO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HSTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart HSTO vs. The Competition Export to ExcelMetricHistogenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2K$864.50M$5.77B$9.93BDividend YieldN/A4.84%6.67%4.52%P/E Ratio0.001.1475.6026.68Price / Sales0.1126.53555.18213.69Price / CashN/A19.5637.1158.92Price / Book0.006.7111.446.09Net Income-$10.62M-$4.20M$3.28B$266.14M7 Day PerformanceN/A0.64%0.84%0.27%1 Month PerformanceN/A11.58%7.15%4.13%1 Year PerformanceN/A28.09%59.65%23.93% Histogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HSTOHistogenN/A$0.00flatN/A-99.8%$2K$19K0.0020Gap UpPXMDPaxMedicaN/A$0.00+100.0%N/AN/A$2KN/A0.002Gap UpCALACalithera BiosciencesN/A$0.00flatN/A-99.0%$1KN/A0.0060CLVRClever LeavesN/A$0.00flatN/AN/A$1K$17.42M0.00560EFTReFFECTOR TherapeuticsN/A$0.00flatN/A-99.4%$1KN/A0.0010ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040ATNFW180 Life SciencesN/A$0.26-5.4%N/A+2,333.7%$0.00N/A0.007Positive NewsGap UpLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.00flatN/AN/A$0.00N/A0.002AIMDWAinosN/A$0.35+45.6%N/AN/A$0.00$110.87K0.0040Positive NewsGap DownALVOWAlvotechN/A$1.19-3.7%N/A-60.4%$0.00$560.10M0.004Positive NewsGap Down Related Companies and Tools Related Companies PaxMedica Competitors Calithera Biosciences Competitors Clever Leaves Competitors eFFECTOR Therapeutics Competitors OncoSec Medical Competitors 180 Life Sciences Competitors 4D pharma Competitors Aesther Healthcare Acquisition Competitors Ainos Competitors Alvotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HSTO) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Histogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Histogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
